CNA938 Rewind - VERS; which estates could be first?
Singapore's economy is set to grow faster than earlier expected this year. That's according to the Ministry of Trade and Industry (MTI), which raised its GDP growth forecast to between 1.5 and 2.5 per cent – up from zero to 2 per cent. But there have been warnings surrounding the outlook for the rest of the year, with global growth likely to slow due to U.S reciprocal tariffs taking effect. Lance Alexander and Daniel Martin speak with Alvin Liew, Senior Economist, UOB.
CNA938 Rewind - Putting on the Ritz & Rizz – Enclave Bar's Founder
In 'Made in SG', Melanie Oliveiro discovers the entrepreneurial journey of Ritz Ang, founder of Enclave a Thai-Singaporean bar and creative space located at 55A Neil Road. Ang will talk about how he got exposed to running a business as a child thanks to his parents who ran a KTV club at the former Golden Mile Complex. He'll then recall establishing Enclave from scratch and perfecting recipes for its signature Thai-inspired bar grub and specialty cocktails. Ang also explains how Enclave is also a cultural hub for creators, thinkers, and nightcrawlers.
CNA938 Rewind - Claire Javier – the singer-songwriter with ties to SG & The Philippines
In 'Culture Club', Melanie Oliveiro speaks with Claire Javier, a rising indie-pop singer-songwriter who'll talk about her music — in particular the new single, 'Easy'. Javier will recall how she composed 'Easy' — a dreamy, tongue-in-cheek track that describes the surreal dream of a past fling. The Filipino-Singaporean will also talk about other single 'misbehave', performing on stage in front of a live audience, and how she has moved from her previous introspective work to a more narrative/confessional form of songwriting. Discover more Singaporean music and musicians – like Claire Javier – at Hear65.com an initiative by the National Arts Council, produced by independent music media company Bandwagon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNA
24 minutes ago
- CNA
J-pop idol Kenshin Kamimura found guilty of indecent assault in Hong Kong
J-pop star Kenshin Kamimura was found guilty by a Hong Kong court on Wednesday (Aug 13) of the indecent assault in March of a woman who served as his interpreter during a fan event. Kamimura, 26, was previously a member of the six-member boy group One N' Only. He pleaded not guilty in April and chose not to testify during the trial in July. Magistrate Peter Yu said that Kamimura's behaviour showed obvious disrespect towards women, noting that his touches suggested a sexual undertone. "Such behaviour should be condemned," Yu said, fining him HK$15,000 (US$1,923) after his lawyer in mitigation urged a financial penalty rather than jail. On hearing the sentence, Kamimura hugged his court translator, while a handful of fans wept in the public gallery. Dozens more waited outside after the hearing ended as Kamimura left court without saying anything. The victim, identified only as X, testified in July that Kamimura and actor Junsei Motojima hired her as an interpreter to translate during a fan meeting in Hong Kong on Mar 1. The group then attended a celebratory dinner at a restaurant in the city's Mong Kok district. She told the court Kamimura moved to sit beside her during a toasting session and started repeatedly brushing and patting her thigh before suggesting they visit the bathroom together. He asked both in Chinese and Japanese if she knew what he meant, she added. X said she declined, telling him, "If you want to go, you can go by yourself." She said she then moved away to get some tea, but Kamimura blocked her path and again asked her to go outside. She told the court she refused. After X returned to her seat, Kamimura also came back and sat beside her. He apologised and said, "Forget what just happened," she recalled in her testimony. The singer also asked her about her relationship status and whether she planned to marry her boyfriend, she said. Kamimura then brushed her inner thigh again with the back of his right hand, X told the court. She shrank away, but he repeated the action about two to three times. Kamimura's lawyer said in mitigation that his client did not intend to coerce or threaten and that alcohol might have affected his judgment. The magistrate said that Kamimura had paid a huge price for the incident, saying he was immediately fired by his company and forced to leave the band.
CNA
2 hours ago
- CNA
Commentary: China is playing the long game on trade. It's working
SINGAPORE: President Donald Trump's trade war was meant to rebalance global power in America's favour. Instead, China is playing the long game, enduring short-term economic pain to shape any eventual deal to its advantage. The strategy appears to be working – for now. On Monday (Aug 11), Washington granted Beijing another 90-day reprieve, extending a pause on tariffs through Nov 10. China announced it would do the same. Markets welcomed the move, which offered some relief after months of tension. The delay will give President Xi Jinping's policymakers more time to plan their next move. Time is Xi's ally. So far, the clearest outcome of each round of talks has been a commitment to meet again. Despite Trump's insistence that China has taken significant steps to improve their trade relationship, Beijing has made no consequential concessions on any of his key concerns. (China has offered some small compromises, none on the scale of American demands.) The extension has come at a delicate time for the economy, which is plagued by sluggish domestic demand and a slowdown in the property sector. Bloomberg Economics says that China is among the few major nations without a clear timeline or terms for a deal, while others have struck agreements to secure lower tariffs. Even with this reprieve, it notes, Beijing faces average US tariffs of 40 per cent – almost 25 percentage points above the global average. This will hurt prospects for Chinese citizens, who have enjoyed more than three decades of near double-digit growth. The economy expanded by 5.2 per cent in April-June from a year earlier – enviable by global standards – but anxieties among the once-thriving middle class over the future for their children are rising. Youth unemployment remains stubbornly high, with joblessness at 14.5 per cent in June. That figure has improved in recent months, but analysts point to significant challenges: More than 12 million university students are set to graduate with hopes of joining the workforce. A LONG BATTLE Still, China is betting that despite these economic costs, it can fight this trade war to the end. Politically, Beijing is preparing the population for a long battle. State media editorials in recent months have lauded a Mao-era philosophy as a possible strategy to counter American pressure. They reference the former Chinese leader's 1938 essay On Protracted War, which laid out his approach to combating the invading Japanese between 1937 and 1945. During a series of lectures in May and June 1938, Mao spoke of how the 'contest of strength is not only a contest of military and economic power, but also a contest of human power and morale'. Scholars say the idea was to alert his fellow citizens that the war would be long and gruelling, but could be won through endurance and unity. Despite millions of Chinese dead, Mao refused to yield. The conflict only ended after Japan surrendered in World War II in 1945. (Mao's civil war with the Nationalists lasted another four years.) Xi appears to be heeding his predecessor's counsel: patience, at all costs – with the aim of shifting the odds in Beijing's favour. CHINA'S STRATEGY OF SELF-RELIANCE Domestically, Xi has the levers of the Chinese state at his disposal to help him craft a now well-worn narrative that the West is keeping China down. The trade war has fuelled those views, which play well with an already disgruntled citizenry. Internationally, Trump is doing much of the work for him. In contrast to Washington's chaos on everything from trade to international students' university admissions, Beijing is presenting itself as a champion of multilateralism – notwithstanding that it's also trying to reshape the world order to its advantage. China is happy to keep the talks going, but is unlikely to make any concessions, as William Yang, the International Crisis Group's senior North East Asia analyst, says in a note. 'China believes momentum is on its side because Trump has a stronger desire to sign a deal with Beijing so that he can claim victory and secure a summit with Xi in the fall.' But Washington's economic leverage is gradually eroding, as China pushes ahead with its strategy of self-reliance. Beijing wants to reduce dependence on US markets, and deepen control over critical supply chains, as a report from the RAND thinktank notes. China on Monday urged local firms to avoid using Nvidia's H20 processors, especially in government projects, following a White House directive requiring it and AMD to pay 15 per cent of Chinese AI chip sales to Washington.
Straits Times
5 hours ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.
